Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis
Malhotra, Sunny (Hospital Universitari Vall d'Hebron)
Fissolo, Nicolás (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Tintoré, Mar (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Wing, Ana Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Castilló, Joaquín (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Vidal-Jordana, Angela (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Montalban, Xavier (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Comabella López, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Fecha:	2015
Resumen:	High mobility group box protein 1 (HMGB1) is a transcriptional regulator that is receiving increasing attention in autoimmune disorders including multiple sclerosis (MS). Here, we investigated the role of HMGB1 in the peripheral blood compartment from MS patients. HMGB1 mRNA expression levels were determined by PCR in peripheral blood mononuclear cells (PBMC) of 29 healthy controls and 57 untreated MS patients (26 with relapsing-remitting MS - RRMS, 13 with secondary progressive MS - SPMS, and 18 with primary progressive MS - PPMS). HMGB1 protein levels were measured by ELISA in serum samples from 18 HC and 37 untreated MS patients (13 with RRMS, 14 with SPMS, and 10 with PPMS). HMGB1 expression levels were increased in PBMC from the whole MS group compared with controls (P = 0. 03). Further stratification of the MS group revealed higher expression levels in PBMC from patients with relapse-onset MS, and differences were statistically significant for RRMS patients compared with PPMS patients and controls (P = 4 × 10 -5 and P = 0. 005, respectively) and also for SPMS patients compared with PPMS patients (P = 0. 001). HMGB1 serum levels were increased in the whole MS group compared with controls (P = 2 × 10 -4). In MS clinical forms, the highest HMGB1 serum levels were observed in RRMS patients, and differences were statistically significant compared to PPMS patients (P = 5 × 10 -5), SPMS patients (P = 0. 001), and controls (P = 0. 001). These results point to a role of HMGB1 mRNA and protein levels as disease activity biomarkers to discriminate the more inflammatory relapse-onset MS forms, particularly RRMS, from the less inflammatory PPMS form of the disease. The online version of this article (doi:10. 1186/s12974-015-0269-9) contains supplementary material, which is available to authorized users.
Nota:	Altres ajuts: The authors thank the 'Red Española de Esclerosis Múltiple (REEM)' sponsored by the 'Fondo de Investigación Sanitaria' (FIS), Ministry of Science and Innovation, Spain, and the 'Ajuts per donar Suport als Grups de Recerca de Catalunya,' sponsored by the 'Agència de Gestió d'Ajuts Universitaris i de Recerca' (AGAUR), Generalitat de Catalunya, Spain.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	High mobility group box protein 1 ; Biomarkers ; Multiple sclerosis
Publicado en:	Journal of neuroinflammation, Vol. 12 (march 2015) , ISSN 1742-2094

DOI: 10.1186/s12974-015-0269-9
PMID: 25879961

5 p, 393.0 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados